1Szalat A, Raz I. Metabolic syndrome and microangiopathy. Isr Med Assoc J 2006; (8) : 424 - 425.
2Bonnet F, Cooper ME. Potential influence of lipids in diabetic nephropathy:insights from experimental data and clinical studies. Diabetes Metab 2000;26(4):254- 264.
3Cameron MA, Maalouf NM, Adams - Huet B, et al. Urine composition in type 2 diabetes:predisposition to uric acid nephrolithiasis. J Am Soc Nephrol 2006; 17(5) : 1422 - 1428.
1Sonkodi S,Mogyorosi A.Treatment of diabetic nephropathy with angiotensin Ⅱ blockers.Nephrol Dial Transplant,2003,18(suppl 5):v21-23.
2Collister JP,Hendel MD.The role of Ang (1-7) in mediating the chronic hypotensive effects of losartan in normal rats.J Renin Angiotensin Aldosterone Syst,2003,4:176-179.
3Taal MW,Brenner BM.Renoprotective benefits of RAS inhibition:from ACEI to angiotensin Ⅱ antagonists.Kidney Int,2000,57:1803-1817.
4Raij L.Recommendations for the management of special populations:renal disease in diabetes.Am J Hypertens,2003,16(11Pt 2):46s-49s.
5Parving HH,Andersen S,Jacobsen P,et al.Angiotensin receptor blockers in diabetic nephropathy:renal and cardiovascular end points.Semin Nephrol,2004,24:147 157.
6Mangrum AJ,Bakris GL.Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic renal disease:safety issues.Semin Nephrol,2004,24:168-175.
